21 results on '"Van Wijk, Michiel"'
Number of results to display per page
Search Results
2. Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement
- Author
-
MS Oogheelkunde, Child Health, Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van Der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H.M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elizabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C.M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, Hennekam, Raoul C., MS Oogheelkunde, Child Health, Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van Der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H.M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elizabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C.M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, and Hennekam, Raoul C.
- Published
- 2024
3. Prevalence of Gastroesophageal Reflux Disease in Congenital Diaphragmatic Hernia Survivors From Infancy to Adulthood
- Author
-
Pulvirenti, Rebecca, Sreeram, Isabel I., van Wijk, Michiel P., IJsselstijn, Hanneke, Kamphuis, Lieke S., Rottier, Robbert J., Wijnen, René M.H., Spaander, Manon C.W., Schnater, J. Marco, Pulvirenti, Rebecca, Sreeram, Isabel I., van Wijk, Michiel P., IJsselstijn, Hanneke, Kamphuis, Lieke S., Rottier, Robbert J., Wijnen, René M.H., Spaander, Manon C.W., and Schnater, J. Marco
- Abstract
Background: Gastroesophageal reflux disease (GERD) is a common comorbidity associated with congenital diaphragmatic hernia (CDH), with reported cases of Barrett's esophagus (BE) and esophageal adenocarcinoma before the age of 25. The prevalence and natural course of GERD in CDH survivors remain uncertain due to variations in diagnostic methods. We aimed to analyse the GERD prevalence from infancy through young adulthood. Methods: We retrospectively analyzed pH-impedance measurements and endoscopic findings in 96 CDH survivors evaluated as routine care using well established clinical protocols. GERD was defined as an abnormal acid exposure time for pH-MII measurements and as presence of reflux esophagitis or BE at upper endoscopy. Clinical data including symptoms at time of follow-up and use of antireflux medication were collected. Results: GERD prevalence remained consistently low (≤10%) across all age groups, yet many patients experienced GER symptoms. Histological abnormalities were observed in 80% of adolescents and young adults, including microscopic esophagitis in 50%. BE was diagnosed in 7% before the age of 18, all had GER symptoms. CDH severity, anatomy at the time of CDH correction, alcohol usage, and smoking did not emerge as significant risk factors for GERD. Conclusions: Given the low GERD prevalence in CDH survivors, a symptom-driven approach to diagnosis and follow-up is warranted. We advise long-term follow-up for all adult patients due to the early onset of BE and the limited evidence available. The longitudinal course and impact of GERD on other long-term CDH-related comorbidities should be explored in larger cohorts.
- Published
- 2024
4. Diagnosis and management in Rubinstein-Taybi syndrome:first international consensus statement
- Author
-
Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van Der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H.M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elizabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C.M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, Hennekam, Raoul C., Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van Der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H.M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elizabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C.M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, and Hennekam, Raoul C.
- Abstract
Rubinstein-Taybi syndrome (RTS) is an archetypical genetic syndrome that is characterised by intellectual disability, well-defined facial features, distal limb anomalies and atypical growth, among numerous other signs and symptoms. It is caused by variants in either of two genes (CREBBP, EP300) which encode for the proteins CBP and p300, which both have a function in transcription regulation and histone acetylation. As a group of international experts and national support groups dedicated to the syndrome, we realised that marked heterogeneity currently exists in clinical and molecular diagnostic approaches and care practices in various parts of the world. Here, we outline a series of recommendations that document the consensus of a group of international experts on clinical diagnostic criteria for types of RTS (RTS1: CREBBP; RTS2: EP300), molecular investigations, long-term management of various particular physical and behavioural issues and care planning. The recommendations as presented here will need to be evaluated for improvements to allow for continued optimisation of diagnostics and care.
- Published
- 2024
5. Navigating global collaboration:challenges faced by the international network on esophageal atresia
- Author
-
Gottrand, Frédéric, Krishnan, Usha, Widenmann, Anke, Blom, Michaela Dellenmark, Dall’Oglio, Luigi, Wijnen, Rene, van Wijk, Michiel, Fruithof, Jo Anne, von Allmen, Daniel, Kovesi, Tom, Faure, Christophe, Gottrand, Frédéric, Krishnan, Usha, Widenmann, Anke, Blom, Michaela Dellenmark, Dall’Oglio, Luigi, Wijnen, Rene, van Wijk, Michiel, Fruithof, Jo Anne, von Allmen, Daniel, Kovesi, Tom, and Faure, Christophe
- Abstract
The International Network on Esophageal Atresia (INoEA) stands as a beacon of collaboration in addressing the complexities of this congenital condition on a global scale. The eleven board members, from various countries (USA, Canada, France, Australia, Italy, Sweden, Germany, and The Netherlands) and backgrounds (pediatric gastroenterology, pediatric surgery, pediatric pulmonology, nursing, and parents) met in a face-to-face symposium in Lille in November 2023, to identify challenges and solutions for improving global collaboration of the network.
- Published
- 2024
6. Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement
- Author
-
Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean-Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H. M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elisabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C. M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, Hennekam, Raoul C., Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean-Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H. M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elisabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C. M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, and Hennekam, Raoul C.
- Abstract
Rubinstein-Taybi syndrome (RTS) is an archetypical genetic syndrome that is characterised by intellectual disability, well-defined facial features, distal limb anomalies and atypical growth, among numerous other signs and symptoms. It is caused by variants in either of two genes (CREBBP, EP300) which encode for the proteins CBP and p300, which both have a function in transcription regulation and histone acetylation. As a group of international experts and national support groups dedicated to the syndrome, we realised that marked heterogeneity currently exists in clinical and molecular diagnostic approaches and care practices in various parts of the world. Here, we outline a series of recommendations that document the consensus of a group of international experts on clinical diagnostic criteria for types of RTS (RTS1: CREBBP; RTS2: EP300), molecular investigations, long-term management of various particular physical and behavioural issues and care planning. The recommendations as presented here will need to be evaluated for improvements to allow for continued optimisation of diagnostics and care.
- Published
- 2024
7. Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement
- Author
-
Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean-Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H. M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elisabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C. M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, Hennekam, Raoul C., Lacombe, Didier, Bloch-Zupan, Agnès, Bredrup, Cecilie, Cooper, Edward B., Houge, Sofia Douzgou, García-Miñaúr, Sixto, Kayserili, Hülya, Larizza, Lidia, Lopez Gonzalez, Vanesa, Menke, Leonie A., Milani, Donatella, Saettini, Francesco, Stevens, Cathy A., Tooke, Lloyd, Van der Zee, Jill A., Van Genderen, Maria M., Van-Gils, Julien, Waite, Jane, Adrien, Jean-Louis, Bartsch, Oliver, Bitoun, Pierre, Bouts, Antonia H. M., Cueto-González, Anna M., Dominguez-Garrido, Elena, Duijkers, Floor A., Fergelot, Patricia, Halstead, Elisabeth, Huisman, Sylvia A., Meossi, Camilla, Mullins, Jo, Nikkel, Sarah M., Oliver, Chris, Prada, Elisabetta, Rei, Alessandra, Riddle, Ilka, Rodriguez-Fonseca, Cristina, Rodríguez Pena, Rebecca, Russell, Janet, Saba, Alicia, Santos-Simarro, Fernando, Simpson, Brittany N., Smith, David F., Stevens, Markus F., Szakszon, Katalin, Taupiac, Emmanuelle, Totaro, Nadia, Valenzuena Palafoll, Irene, Van Der Kaay, Daniëlle C. M., Van Wijk, Michiel P., Vyshka, Klea, Wiley, Susan, and Hennekam, Raoul C.
- Abstract
Rubinstein-Taybi syndrome (RTS) is an archetypical genetic syndrome that is characterised by intellectual disability, well-defined facial features, distal limb anomalies and atypical growth, among numerous other signs and symptoms. It is caused by variants in either of two genes (CREBBP, EP300) which encode for the proteins CBP and p300, which both have a function in transcription regulation and histone acetylation. As a group of international experts and national support groups dedicated to the syndrome, we realised that marked heterogeneity currently exists in clinical and molecular diagnostic approaches and care practices in various parts of the world. Here, we outline a series of recommendations that document the consensus of a group of international experts on clinical diagnostic criteria for types of RTS (RTS1: CREBBP; RTS2: EP300), molecular investigations, long-term management of various particular physical and behavioural issues and care planning. The recommendations as presented here will need to be evaluated for improvements to allow for continued optimisation of diagnostics and care.
- Published
- 2024
8. Randomised clinical trial:First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease
- Author
-
Vuijk, Stephanie A., Jongsma, Maria M.E., Hoeven, Britt M., Cozijnsen, Maarten A., van Pieterson, Merel, de Meij, Tim G.J., Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert, Hummel, Thalia, Stapelbroek, Janneke, van der Feen, Cathelijne, van Rheenen, Patrick F., van Wijk, Michiel P., Teklenburg, Sarah, Rizopoulos, Dimitris, Poley, Marten J., Escher, Johanna C., de Ridder, Lissy, Vuijk, Stephanie A., Jongsma, Maria M.E., Hoeven, Britt M., Cozijnsen, Maarten A., van Pieterson, Merel, de Meij, Tim G.J., Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert, Hummel, Thalia, Stapelbroek, Janneke, van der Feen, Cathelijne, van Rheenen, Patrick F., van Wijk, Michiel P., Teklenburg, Sarah, Rizopoulos, Dimitris, Poley, Marten J., Escher, Johanna C., and de Ridder, Lissy
- Abstract
Background: Data on cost-effectiveness of first-line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed.Aim: To investigate the cost-effectiveness of first-line infliximab compared to conventional treatment in children with moderate-to-severe Crohn's disease. Methods:We included patients from the Top-down Infliximab Study in Kids with Crohn's disease randomised controlled trial. Children with newly diagnosed moderate-to-severe Crohn's disease were treated with azathioprine maintenance and either five induction infliximab (biosimilar) infusions or conventional induction treatment (exclusive enteral nutrition or corticosteroids). Direct healthcare consumption and costs were obtained per patient until week 104. This included data on outpatient hospital visits, hospital admissions, drug costs, endoscopies and surgeries. The primary health outcome was the odds ratio of being in clinical remission (weighted paediatric Crohn's disease activity index<12.5) during 104 weeks. Results: We included 89 patients (44 in the first-line infliximab group and 45 in the conventional treatment group). Mean direct healthcare costs per patient were €36,784 for first-line infliximab treatment and €36,874 for conventional treatment over 2 years (p = 0.981). The odds ratio of first-line infliximab versus conventional treatment to be in clinical remission over 104 weeks was 1.56 (95%CI 1.03–2.35, p = 0.036). Conclusions: First-line infliximab treatment resulted in higher odds of being in clinical remission without being more expensive, making it the dominant strategy over conventional treatment in the first 2 years after diagnosis in children with moderate-to-severe Crohn's disease. Trial registration number: NCT02517684.
- Published
- 2024
9. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
- Author
-
Jongsma, Maria M.E., Vuijk, Stephanie A., Cozijnsen, Martinus A., van Pieterson, Merel, Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija Leena, van Wijk, Michiel P., Teklenburg-Roord, Sarah T.A., de Meij, Tim G.J., Escher, Johanna C., de Ridder, Lissy, Jongsma, Maria M.E., Vuijk, Stephanie A., Cozijnsen, Martinus A., van Pieterson, Merel, Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija Leena, van Wijk, Michiel P., Teklenburg-Roord, Sarah T.A., de Meij, Tim G.J., Escher, Johanna C., and de Ridder, Lissy
- Abstract
To induce remission in luminal paediatric Crohn’s disease (CD), the ESPGHAN/ECCO guideline recommends treatment with exclusive enteral nutrition (EEN) or oral corticosteroids. In newly diagnosed moderate-to-severe paediatric CD patients, we determined the proportion of patients in which EEN or corticosteroids induced remission and maintained remission on azathioprine monotherapy. We included patients from the “TISKids” study assigned to the conventional treatment arm. Patients were aged 3–17 years and had new-onset, untreated luminal CD with weighted paediatric CD activity index (wPCDAI) > 40. Induction treatment consisted of EEN or oral corticosteroids; all received azathioprine maintenance treatment from start of treatment. The primary outcome of this study was endoscopic remission defined as a SES-CD score < 3 without treatment escalation at week 10. Secondary outcomes included proportion of patients without treatment escalation at week 52. In total, 27/47 patients received EEN and 20/47 corticosteroids. At baseline, patient demographics and several inflammation parameters were similar between the two treatment groups. At 10 weeks, clinical remission rates were 7/23 (30%) for EEN and 7/19 (37%) for corticosteroids (p = 0.661). Twenty-nine of 47 consented to endoscopy at 10 weeks, showing endoscopic remission rates without treatment escalation in 2/16 (13%) of EEN-treated patients and in 1/13 (8%) of corticosteroid-treated patients (p = 1.00). At week 52, 23/27 (85%) EEN-treated patients received treatment escalation (median 14 weeks) and 13/20 (65%) corticosteroid-treated patients (median 27 weeks), p = 0.070. Conclusion: In children with moderate-to-severe newly diagnosed CD, induction treatment with EEN or CS regularly is insufficient to achieve endoscopic remission without treatment escalation at week 10. Trial registration number: NCT02517684 What is Known:• Endoscopic remission is associated with a low risk of disease progression.• FL-IFX was superi
- Published
- 2022
10. Psychometric Performance of a Condition-Specific Quality-of-Life Instrument for Dutch Children Born with Esophageal Atresia
- Author
-
ten Kate, Chantal A., IJsselstijn, Hanneke, Dellenmark-Blom, Michaela, van Tuyll van Serooskerken, E. Sofie, Joosten, Maja, Wijnen, René M.H., van Wijk, Michiel P., ten Kate, Chantal A., IJsselstijn, Hanneke, Dellenmark-Blom, Michaela, van Tuyll van Serooskerken, E. Sofie, Joosten, Maja, Wijnen, René M.H., and van Wijk, Michiel P.
- Abstract
A
- Published
- 2022
11. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease:An open-label multicentre randomised controlled trial
- Author
-
Jongsma, Maria M.E., Aardoom, Martine A., Cozijnsen, Martinus A., Van Pieterson, Merel, De Meij, Tim, Groeneweg, Michael, Norbruis, Obbe F., Wolters, Victorien M., Van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija Leena, Hummel, Thalia, Stapelbroek, Janneke, Van Der Feen, Cathelijne, Van Rheenen, Patrick F., Van Wijk, Michiel P., Teklenburg-Roord, Sarah T.A., Schreurs, Marco W.J., Rizopoulos, Dimitris, Doukas, Michail, Escher, Johanna C., Samsom, Janneke N., De Ridder, Lissy, Jongsma, Maria M.E., Aardoom, Martine A., Cozijnsen, Martinus A., Van Pieterson, Merel, De Meij, Tim, Groeneweg, Michael, Norbruis, Obbe F., Wolters, Victorien M., Van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija Leena, Hummel, Thalia, Stapelbroek, Janneke, Van Der Feen, Cathelijne, Van Rheenen, Patrick F., Van Wijk, Michiel P., Teklenburg-Roord, Sarah T.A., Schreurs, Marco W.J., Rizopoulos, Dimitris, Doukas, Michail, Escher, Johanna C., Samsom, Janneke N., and De Ridder, Lissy
- Abstract
In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. We aimed to investigate whether starting first-line IFX (FL-IFX) is more effective to achieve and maintain remission than conventional treatment. Design In this multicentre open-label randomised controlled trial, untreated patients with a new diagnosis of CD (3-17 years old, weighted Paediatric CD Activity Index score (wPCDAI) >40) were assigned to groups that received five infusions of 5 mg/kg IFX at weeks 0, 2, 6, 14 and 22 (FL-IFX), or EEN or oral prednisolone (1 mg/kg, maximum 40 mg) (conventional). The primary outcome was clinical remission on azathioprine, defined as a wPCDAI <12.5 at week 52, without need for treatment escalation, using intention-to-treat analysis. Results 100 patients were included, 50 in the FL-IFX group and 50 in the conventional group. Four patients did not receive treatment as per protocol. At week 10, a higher proportion of patients in the FL-IFX group than in the conventional group achieved clinical (59% vs 34%, respectively, p=0.021) and endoscopic remission (59% vs 17%, respectively, p=0.001). At week 52, the proportion of patients in clinical remission was not significantly different (p=0.421). However, 19/46 (41%) patients in the FL-IFX group were in clinical remission on azathioprine monotherapy without need for treatment escalation vs 7/48 (15%) in the conventional group (p=0.004). Conclusions FL-IFX was superior to conventional treatment in achieving short-term clinical and endoscopic remission, and had greater likelihood of maintaining clinical remission at week 52 on azathioprine monotherapy. Trial registration number ClinicalTrials.gov Registry (NCT02517684).
- Published
- 2022
12. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
- Author
-
MDL onderzoek 1, MDL patientenzorg, MDL, Child Health, Jongsma, Maria M.E., Vuijk, Stephanie A., Cozijnsen, Martinus A., van Pieterson, Merel, Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija Leena, van Wijk, Michiel P., Teklenburg-Roord, Sarah T.A., de Meij, Tim G.J., Escher, Johanna C., de Ridder, Lissy, MDL onderzoek 1, MDL patientenzorg, MDL, Child Health, Jongsma, Maria M.E., Vuijk, Stephanie A., Cozijnsen, Martinus A., van Pieterson, Merel, Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija Leena, van Wijk, Michiel P., Teklenburg-Roord, Sarah T.A., de Meij, Tim G.J., Escher, Johanna C., and de Ridder, Lissy
- Published
- 2022
13. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial
- Author
-
MDL, Child Health, Jongsma, Maria M E, Aardoom, Martine A, Cozijnsen, Martinus A, van Pieterson, Merel, de Meij, Tim, Groeneweg, Michael, Norbruis, Obbe F, Wolters, Victorien M, van Wering, Herbert M, Hojsak, Iva, Kolho, Kaija-Leena, Hummel, Thalia, Stapelbroek, Janneke, van der Feen, Cathelijne, van Rheenen, Patrick F, van Wijk, Michiel P, Teklenburg-Roord, Sarah T A, Schreurs, Marco W J, Rizopoulos, Dimitris, Doukas, Michail, Escher, Johanna C, Samsom, Janneke N, de Ridder, Lissy, MDL, Child Health, Jongsma, Maria M E, Aardoom, Martine A, Cozijnsen, Martinus A, van Pieterson, Merel, de Meij, Tim, Groeneweg, Michael, Norbruis, Obbe F, Wolters, Victorien M, van Wering, Herbert M, Hojsak, Iva, Kolho, Kaija-Leena, Hummel, Thalia, Stapelbroek, Janneke, van der Feen, Cathelijne, van Rheenen, Patrick F, van Wijk, Michiel P, Teklenburg-Roord, Sarah T A, Schreurs, Marco W J, Rizopoulos, Dimitris, Doukas, Michail, Escher, Johanna C, Samsom, Janneke N, and de Ridder, Lissy
- Published
- 2020
14. Pediatric Achalasia in the Netherlands : Incidence, Clinical Course, and Quality of Life
- Author
-
Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, van Wijk, Michiel, Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, and van Wijk, Michiel
- Published
- 2016
15. Pediatric Achalasia in the Netherlands : Incidence, Clinical Course, and Quality of Life
- Author
-
Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, van Wijk, Michiel, Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, and van Wijk, Michiel
- Published
- 2016
16. Pediatric Achalasia in the Netherlands : Incidence, Clinical Course, and Quality of Life
- Author
-
Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, van Wijk, Michiel, Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, and van Wijk, Michiel
- Published
- 2016
17. Pediatric Achalasia in the Netherlands: Incidence, Clinical Course, and Quality of Life
- Author
-
Child Health, Cluster C, MDL patientenzorg, Zorgeenheid Kinderchirurgie Medisch, Other research (not in main researchprogram), Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, van Wijk, Michiel, Child Health, Cluster C, MDL patientenzorg, Zorgeenheid Kinderchirurgie Medisch, Other research (not in main researchprogram), Smits, Marije, van Lennep, Marinde, Vrijlandt, Remy, Benninga, Marc, Oors, Jac, Houwen, RHJ, Kokke, Freddy, van der Zee, David, Escher, Johanne, van den Neucker, Anita, de Meij, Tim, Bodewes, Frank, Schweizer, Joachim, Damen, Gerard, Busch, Olivier, and van Wijk, Michiel
- Published
- 2016
18. Pediatric Achalasia: Diagnosis, Management and Follow-Up in the Netherlands
- Author
-
Arts-assistenten Kinderen, Child Health, MDL, Zorgeenheid Kinderchirurgie Medisch, Other research (not in main researchprogram), Smits, MJ, van Lennep, Marinde, Benninga, Marc A, Houwen, RHJ, Kokke, FTM, van der Zee, DC, Bodewes, Frank A. J. A., Van den Neucker, Anita M., de Meij, Tim, Schweizer, J.J., Escher, Johanna C., Damen, Gerard M, van Wijk, Michiel, Arts-assistenten Kinderen, Child Health, MDL, Zorgeenheid Kinderchirurgie Medisch, Other research (not in main researchprogram), Smits, MJ, van Lennep, Marinde, Benninga, Marc A, Houwen, RHJ, Kokke, FTM, van der Zee, DC, Bodewes, Frank A. J. A., Van den Neucker, Anita M., de Meij, Tim, Schweizer, J.J., Escher, Johanna C., Damen, Gerard M, and van Wijk, Michiel
- Published
- 2015
19. The impact of induced plant volatiles on plant-arthropod interactions
- Author
-
0000-0003-4822-9827, Alba, Juan M., Bleeker, Petra M., Glas, Joris J., Schimmel, Bernardus C.J., van Wijk, Michiel, Sabelis, Maurice W., Schuurink, Robert C., Kant, Merijn R., 0000-0003-4822-9827, Alba, Juan M., Bleeker, Petra M., Glas, Joris J., Schimmel, Bernardus C.J., van Wijk, Michiel, Sabelis, Maurice W., Schuurink, Robert C., and Kant, Merijn R.
- Abstract
Plants release volatile organic compounds from their vegetative tissues into their environment during most of their life cycle. The functions of these volatiles are diverse and not always known but some of these volatiles repel foraging herbivores while others, in turn, attract them and are feeding stimuli. Upon herbivory the amount of volatiles increases dramatically while, simultaneously, also the composition of the blend changes thereby enhancing the attractiveness of the plant to foraging natural enemies and in some cases increasing repellency to herbivores. Hence, herbivore-induced volatiles promote a natural form of biological pest control referred to as “indirect plant defense” and it has often been suggested that this phenomenon could be exploited to enhance crop protection. Here we will introduce the concept of indirect plant defense via volatiles and via other means and outline the current state of knowledge to the extent in which it contributes to protecting a plant to maximize its fitness under natural conditions in an evolutionary and ecological context. Moreover we will summarize the different approaches that have been undertaken to manipulate indirect defenses, either via application of synthetic volatiles or via transgenic manipulation of plant-volatile production, to control the movements of foraging arthropods to improve biological control. Finally, we will discuss to which extent IPM can be improved or even be disrupted via manipulation of plant volatiles.
- Published
- 2012
20. Herbivore-Specific, Density-Dependent Induction of Plant Volatiles: Honest or “Cry Wolf” Signals?
- Author
-
10591208, 10197197, Shiojiri, Kaori, Ozawa, Rika, Kugimiya, Soichi, Uefune, Masayoshi, van Wijk, Michiel, Sabelis, Maurice W., Takabayashi, Junji, 10591208, 10197197, Shiojiri, Kaori, Ozawa, Rika, Kugimiya, Soichi, Uefune, Masayoshi, van Wijk, Michiel, Sabelis, Maurice W., and Takabayashi, Junji
- Abstract
Plants release volatile chemicals upon attack by herbivorous arthropods. They do so commonly in a dose-dependent manner: the more herbivores, the more volatiles released. The volatiles attract predatory arthropods and the amount determines the probability of predator response. We show that seedlings of a cabbage variety (Brassica oleracea var. capitata, cv Shikidori) also show such a response to the density of cabbage white (Pieris rapae) larvae and attract more (naive) parasitoids (Cotesia glomerata) when there are more herbivores on the plant. However, when attacked by diamondback moth (Plutella xylostella) larvae, seedlings of the same variety (cv Shikidori) release volatiles, the total amount of which is high and constant and thus independent of caterpillar density, and naive parasitoids (Cotesia vestalis) of diamondback moth larvae fail to discriminate herbivore-rich from herbivore-poor plants. In contrast, seedlings of another cabbage variety of B. oleracea (var. acephala: kale) respond in a dose-dependent manner to the density of diamondback moth larvae and attract more parasitoids when there are more herbivores. Assuming these responses of the cabbage cultivars reflect behaviour of at least some genotypes of wild plants, we provide arguments why the behaviour of kale (B. oleracea var acephala) is best interpreted as an honest signaling strategy and that of cabbage cv Shikidori (B. oleracea var capitata) as a “cry wolf” signaling strategy, implying a conflict of interest between the plant and the enemies of its herbivores: the plant profits from being visited by the herbivore's enemies, but the latter would be better off by visiting other plants with more herbivores. If so, evolutionary theory on alarm signaling predicts consequences of major interest to students of plant protection, tritrophic systems and communication alike.
- Published
- 2010
21. Groene opties : 8 case-studies van veilige, milieuvriendelijke producten op basis van hernieuwbare grondstoffen
- Author
-
Loomans, E., Vellema, S., van Wijk, Michiel, Minère, L., Loomans, E., Vellema, S., van Wijk, Michiel, and Minère, L.
- Published
- 2001
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.